000151304 001__ 151304 000151304 005__ 20251017144615.0 000151304 0247_ $$2doi$$a10.20986/RESED.2021.3824/2020 000151304 0248_ $$2sideral$$a124270 000151304 037__ $$aART-2021-124270 000151304 041__ $$aeng 000151304 100__ $$aLópez, R. 000151304 245__ $$aManagement and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain [Manejo y percepción de la adherencia al tratamiento del dolor irruptivo oncológico por oncólogos españoles] 000151304 260__ $$c2021 000151304 5060_ $$aAccess copy available to the general public$$fUnrestricted 000151304 5203_ $$aObjectives: The objective of this study was to evaluate the perception of oncologists on adherence to opioid treatment for breakthrough cancer pain (BTcP) in current clinical practice. Our study also included an assessment of other aspects of the management of BTcP, such as the reasons for non-adherence, the adequacy of the treatment, or the possible interventions required to improve adherence. Methods: This observational, multicentric study was carried out in 84 hospitals throughout Spain. Oncologists were surveyed by means of an online questionnaire on their management of background cancer pain and BTcP, and their perception of adherence to the treatments.Results: Oncologists (N = 97) reported that their first choice for BTcP was fentanyl (various formulations), with high perceived tolerance (> 76 % of patients). Most oncologists (96.8 %) evaluated adherence in their patients but only 69. 1% always prescribed medication to prevent adverse effects of opioids and only 74.2 % always titrated the minimum dose. Most oncologists (51.0 %) perceived that 25-50 % of the patients did not adhere to the treatment for BTcP. Adherence to background pain treatments was high, although many oncologists considered that patients usually stopped taking the medication when feeling better. The main reported reasons for non-adherence were the self-perceived feeling that treatment was unnecessary, perceived inefficacy of the treatment, concerns about potential adverse effects, and lack of family support. Conclusions: Oncologists perceived that adherenceto BTcP treatment can be improved and recommended treatment of adverse effects, better education about pain management to patients and relatives, written prescription instructions, and simplification of drug regimens. 000151304 540__ $$9info:eu-repo/semantics/openAccess$$aby-nd$$uhttps://creativecommons.org/licenses/by-nd/4.0/deed.es 000151304 592__ $$a0.125$$b2021 000151304 593__ $$aAnesthesiology and Pain Medicine$$c2021$$dQ4 000151304 594__ $$a0.3$$b2021 000151304 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000151304 700__ $$aBorrega, P. 000151304 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza 000151304 700__ $$aAranda, E. 000151304 700__ $$aCarrato, A. 000151304 700__ $$aConstenla, M.I. 000151304 700__ $$aCruz, J.J. 000151304 700__ $$aDíaz-Rubio, E. 000151304 700__ $$aFeyjóo, M. 000151304 700__ $$aGarcía-Foncillas, J. 000151304 700__ $$aGascón, P. 000151304 700__ $$aGuillem, V. 000151304 700__ $$aCamps, C. 000151304 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000151304 773__ $$g28, 1 (2021), 19-26$$pRev. Soc. Esp. Dolor$$tRevista de la Sociedad Española del Dolor$$x1134-8046 000151304 8564_ $$s611658$$uhttps://zaguan.unizar.es/record/151304/files/texto_completo.pdf$$yVersión publicada 000151304 8564_ $$s2561809$$uhttps://zaguan.unizar.es/record/151304/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000151304 909CO $$ooai:zaguan.unizar.es:151304$$particulos$$pdriver 000151304 951__ $$a2025-10-17-14:19:11 000151304 980__ $$aARTICLE